Jarett Berry, MD
Cardiovascular Disease · Tyler, TXNPI 1134345275
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,400 of the $5,598 with a category attached, or 78.6%. Roche Diagnostics Corporation accounts for 99.2% of it on its own, with 2 other manufacturers making up the rest.
Across 9 payments — averaging $622.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$6K
- Abiomed$31
- Boehringer Ingelheim$14
Across 1 payment — averaging $1,425,485 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Corporation$1.4M
What the payments were for
- Consulting fees$4,40079%
- Travel & lodging$62111%
- Food & beverage$57710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 7 | $5,553 |
| Abiomed | 1 | $31 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CD cobas Reagents$5,445
How this compares
$5,598 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 11 | $130 |
| Carvedilol | 14 | $99 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Tyler
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.